Seattle's Juno Therapeutics Pauses Trial After Patient Deaths
4/9/2014 7:07:21 AM
One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient’s own immune cells to destroy tumors. Several companies are racing to commercialize this technology. In the lead are Novartis NVS +1.09%, working with researchers at the University of Pennsylvania, and Juno Therapeutics, a roll-up of research at Memorial Sloan-Kettering Cancer Center In New York and the Fred Hutchinson Cancer Research Center in Seattle that raised $145 million from investors including Jeff Bezos earlier this year. The team of Celgene CELG -0.65% and Bluebird has also entered the field, as has Kite Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
comments powered by